QR-Code

Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease

Tavapadon, a novel oral dopamine-D1R/D5R partial agonist, has been studied in recent years for the treatment of late-stage development Parkinson’s disease (PD). Levodopa, a dopamine precursor that currently remains the gold-standard first-line therapy for PD motor symptoms, serves as a benchmark aga...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Alan D. Kaye, Bennett M. Ford, Brennan M. Abbott, Kalob M. Broocks, Sofia Novacic, Sahar Shekoohi
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2025-09-01
Schriftenreihe:Diseases
Schlagworte:
Parkinson’s disease
Tavapadon
dopamine agonist
D1 receptor
clinical trials
motor symptoms
Online-Zugang:https://www.mdpi.com/2079-9721/13/9/290
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge